BBR Partners’s Allogene Therapeutics ALLO Stock Holding History

BBR Partners’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.2K	Hold	28,952	–	–	﹤0.01%	246
2026 Q1	$70.6K	Hold	28,952	–	–	﹤0.01%	249
2025 Q4	$39.7K	Hold	28,952	–	–	﹤0.01%	265
2025 Q3	$35.9K	Hold	28,952	–	–	﹤0.01%	268
2025 Q2	$32.7K	Hold	28,952	–	–	﹤0.01%	235
2025 Q1	$42.3K	Hold	28,952	–	–	﹤0.01%	240
2024 Q4	$61.7K	Hold	28,952	–	–	﹤0.01%	243
2024 Q3	$81.1K	Hold	28,952	–	–	0.01%	234
2024 Q2	$67.5K	Hold	28,952	–	–	0.01%	212
2024 Q1	$129K	Hold	28,952	–	–	0.01%	241
2023 Q4	$92.9K	Hold	28,952	–	–	0.01%	184
2023 Q3	$91.8K	Hold	28,952	–	–	0.01%	188
2023 Q2	$144K	Hold	28,952	–	–	0.02%	151
2023 Q1	$143K	Hold	28,952	–	–	0.02%	157
2022 Q4	$182K	Hold	28,952	–	–	0.02%	165
2022 Q3	$313K	Hold	28,952	–	–	0.04%	134
2022 Q2	$330K	Hold	28,952	–	–	0.04%	165
2022 Q1	$264K	Sell	28,952 -35,053	-55%	-$365K	0.02%	197
2021 Q4	$955K	Buy	64,005 +28,952	+83%	+$511K	0.11%	83
2021 Q3	$901K	Sell	35,053 -3,955	-10%	-$93.9K	0.07%	99
2021 Q2	$1.02M	Hold	39,008	–	–	0.08%	94
2021 Q1	$1.38M	Buy	+39,008	New	+$1.32M	0.11%	73

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BBR Partners's ALLO Position: Q2 2026 in Review

BBR Partners held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 28,952 shares worth $60.2K. The position accounts for ﹤0.01% of the portfolio, ranked #246.

BBR Partners first reported a position in ALLO in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.38M in Q1 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

BBR Partners held 28,952 shares of Allogene Therapeutics worth $60.2K as of Q2 2026.
BBR Partners left its Allogene Therapeutics share count unchanged in Q2 2026.
Allogene Therapeutics made up ﹤0.01% of BBR Partners's portfolio in Q2 2026, its #246 holding.
BBR Partners first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 22 quarters since.
BBR Partners's Allogene Therapeutics position peaked at $1.38M in Q1 2021.
210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on BBR Partners's 13F filing for Q2 2026, filed 11 Aug 2026.